Page 113 - GPD-3-3

Gene & Protein in Disease Exploring serum inflammatory biomarkers in GBM

(ii) Statistical significance may be observed in specific NIH intramural IRB is IRB00011862. Informed consent
patient sub-cohorts, e.g., patients with methylated was obtained for all subjects before this study.
MGMT or larger tumor burdens.
(iii) IL-6 may have mechanistic links with other statistically Consent for publication
significant markers, as noted in this analysis, where All subjects gave consent to publish their data in this study.
it emerged as a dominant functional unit in IPA
pathways. Availability of data
(iv) IL-6 may play critical functional roles but exhibit Responsible data sharing is part of our mandate and the
divergent behavior in patient cohorts, e.g., patients cardinal future direction of this dataset. We are currently
with more radio- or chemo-resistant disease, aggregating several data aspects including additional
suggesting that its significance may only become
apparent when adjusting for specific clinical features samples and omic data and once this is complete, the set
in future analyses. will be de-identified and shared. The goal is to provide one
comprehensive GBM dataset that has clinical, omic, and
Further research is needed to understand how IL-6 imaging data. Individual requests to access the datasets
may function as a potential driver of the observed signal should be directed to the corresponding author.
alterations and how these are linked to APR pathways.
The role of IL-6 as a possible mediator of tumor References
microenvironment reprogramming, in conjunction with 1. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU.
TNF-α and VCAM-1, requires larger data sets and the Glioblastoma multiforme: A review of its epidemiology and
sharing of serum data. Nonetheless, the current analysis pathogenesis through clinical presentation and treatment.
revealed a balancing act between pro-apoptotic, anti- Asian Pac J Cancer Prev. 2017;18(1):3-9.
proliferative, and pro-viability pathways through STAT3 doi: 10.22034/apjcp.2017.18.1.3
and NF-κB pathways, which may serve as potential
avenues to monitor treatment in GBM and design targeted 2. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor
therapies that may improve outcomes. Further studies heterogeneity in human glioblastoma reflects cancer
in conjunction with clinical data and validation in larger evolutionary dynamics. Proc Natl Acad Sci U S A.
2013;110(10):4009-4014.
datasets are needed to explore these possibilities.
doi: 10.1073/pnas.1219747110
Acknowledgments 3. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends
None. in the medical management of glioblastoma multiforme:
The role of temozolomide chemotherapy. Neurosurg Focus.
Funding 2006;20(4):E6.

Funding is provided in part by the NCI NIH intramural doi: 10.3171/foc.2006.20.4.3
program (ZID BC 010990). 4. McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI.
Radiation, inflammation and the immune response in
Conflict of interest cancer. Mamm Genome. 2018;29(11-12):843-865.
The authors declare that they have no competing interests. doi: 10.1007/s00335-018-9777-0

Author contributions 5. Serban GM, Tamas CI, Tamas F, Balasa AF. preoperative
immune-inflammatory status of the patients with newly-
Conceptualization: Sarisha Jagasia, Andra V. Krauze diagnosed glioblastoma - could it genuinely predict their
Investigation: Sarisha Jagasia, Jason Shephard, Andra V. survival? Cureus. 2023;15(8):e43802.
Krauze doi: 10.7759/cureus.43802
Methodology: Sarisha Jagasia, Andra V. Krauze
Writing – original draft: Sarisha Jagasia, Andra V. Krauze 6. Knebel FH, Uno M, Galatro TF, et al. Serum amyloid A1
is upregulated in human glioblastoma. J Neurooncol.
Writing – review & editing: All authors 2017;132(3):383-391.
Ethics approval and consent to participate doi: 10.1007/s11060-017-2386-z

Most of the GBM patients involved in this study are 7. Linhares P, Carvalho B, Vaz R, Costa BM. Glioblastoma: Is
deceased; however, all patients were treated on NCI NIH there any blood biomarker with true clinical relevance? Int J
IRB-approved protocols, and there is no identifiable Mol Sci. 2020;21(16):5809.
information present in the article. The IRB number for the doi: 10.3390/ijms21165809

Volume 3 Issue 3 (2024) 13 doi: 10.36922/gpd.3580